The purpose of this study is to prospectively determine the diagnostic value of Xenetix-CT perfusion for the discrimination between well-differentiated hepatocellular carcinomas (HCC) and poorly/moderately differentiated HCC, in histo-pathologically proven HCC, and with the aim to cover the entire liver.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
96
Injection of 50 ml of Xenetix
AKH
Vienna, Austria
Universitätsklinikum Erlangen
Erlangen, Germany
SMC
Seoul, South Korea
SNUH
Seoul, South Korea
Zurich University Hospital
Zurich, Switzerland
Blood Volume (BV) According to Degree of Lesions Differentiation
The mean level of each CT perfusion parameter was compared between well differentiated and moderately/poorly differentiated lesions according to WHO classification evaluated off-site.
Time frame: Within a week from CT perfusion to surgery
Blood Flow (BF) According to Degree of Lesions Differentiation
The mean level of each CT perfusion parameter was compared between well differentiated and moderately/poorly differentiated lesions according to WHO classification evaluated off-site.
Time frame: Within a week from CT perfusion to surgery
Permeability Surface (PS) According to Degree of Lesions Differentiation
The mean level of each CT perfusion parameter was compared between well differentiated and moderately/poorly differentiated lesions according to WHO classification evaluated off-site.
Time frame: Within a week from CT perfusion to surgery
Arterial Liver Perfusion (ALP) According to Degree of Lesions Differentiation
The mean level of each CT perfusion parameter was compared between well differentiated and moderately/poorly differentiated lesions according to WHO classification evaluated off-site.
Time frame: Within a week from CT perfusion to surgery
Portal Venous Liver Perfusion (PVP) According to Degree of Lesions Differentiation
The mean level of each CT perfusion parameter was compared between well differentiated and moderately/poorly differentiated lesions according to WHO classification evaluated off-site.
Time frame: Within a week from CT perfusion to surgery
Total Liver Perfusion (TLP) According to Degree of Lesions Differentiation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The mean level of each CT perfusion parameter was compared between well differentiated and moderately/poorly differentiated lesions according to WHO classification evaluated off-site. TLP = ALP + PVP
Time frame: Within a week from CT perfusion to surgery
Hepatic Perfusion Index (HPI) According to Degree of Lesions Differentiation
The mean level of each CT perfusion parameter was compared between well differentiated and moderately/poorly differentiated lesions according to WHO classification evaluated off-site.
Time frame: Within a week from CT perfusion to surgery
Blood Volume According to Immunohistochemistry Parameter (Glutamine Synthetase)
Glutamine synthetase is an immunohistochemistry parameter of hepatocellular carcinoma phenotype. Glutamine synthetase labelling was quantified and in case of positive quantification, classified in the following categories: 1-10%, 10-50% and \>50%. In case of absence of glutamine synthetase labelling, lesions were classified in the "glutamine synthetase 0%" category.
Time frame: Within a week from CT perfusion to surgery
Blood Volume According to Immunohistochemistry Parameter (CD31)
CD31 is an immunohistochemistry marker of microvessel density. CD31 labelling was quantified and in case of positive quantification, classified in the following categories: 1-10%, 10-50% and \>50%. In case of absence of CD31 labelling, lesions were classified in the "CD31 0%" category.
Time frame: Within a week from CT perfusion to surgery
Blood Flow According to Immunohistochemistry Parameter (Glutamine Synthetase)
Glutamine synthetase is an immunohistochemistry parameter of hepatocellular carcinoma phenotype. Glutamine synthetase labelling was quantified and in case of positive quantification, classified in the following categories: 1-10%, 10-50% and \>50%. In case of absence of glutamine synthetase labelling, lesions were classified in the "glutamine synthetase 0%" category.
Time frame: Within a week from CT perfusion to surgery
Blood Flow According to Immunohistochemistry Parameter (CD31)
CD31 is an immunohistochemistry marker of microvessel density. CD31 labelling was quantified and in case of positive quantification, classified in the following categories: 1-10%, 10-50% and \>50%. In case of absence of CD31 labelling, lesions were classified in the "CD31 0%" category.
Time frame: Within a week from CT perfusion to surgery
Permeability Surface According to Immunohistochemistry Parameter (Glutamine Synthetase)
Glutamine synthetase is an immunohistochemistry parameter of hepatocellular carcinoma phenotype. Glutamine synthetase labelling was quantified and in case of positive quantification, classified in the following categories: 1-10%, 10-50% and \>50%. In case of absence of glutamine synthetase labelling, lesions were classified in the "glutamine synthetase 0%" category.
Time frame: Within a week from CT perfusion to surgery
Permeability Surface According to Immunohistochemistry Parameter (CD31)
CD31 is an immunohistochemistry marker of microvessel density. CD31 labelling was quantified and in case of positive quantification, classified in the following categories: 1-10%, 10-50% and \>50%. In case of absence of CD31 labelling, lesions were classified in the "CD31 0%" category.
Time frame: Within a week from CT perfusion to surgery